• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

333例患者卵巢癌易感基因致病变异的谱型及患病率

Spectrum and Prevalence of Pathogenic Variants in Ovarian Cancer Susceptibility Genes in a Group of 333 Patients.

作者信息

Koczkowska Magdalena, Krawczynska Natalia, Stukan Maciej, Kuzniacka Alina, Brozek Izabela, Sniadecki Marcin, Debniak Jaroslaw, Wydra Dariusz, Biernat Wojciech, Kozlowski Piotr, Limon Janusz, Wasag Bartosz, Ratajska Magdalena

机构信息

Department of Biology and Medical Genetics, Medical University of Gdansk, Debinki 1 St., 80-210 Gdansk, Poland.

Laboratory of Clinical Genetics, University Clinical Centre, Smoluchowskiego 17 St., 80-952 Gdansk, Poland.

出版信息

Cancers (Basel). 2018 Nov 14;10(11):442. doi: 10.3390/cancers10110442.

DOI:10.3390/cancers10110442
PMID:30441849
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6266089/
Abstract

Constitutional loss-of-function pathogenic variants in the tumor suppressor genes and are widely associated with an elevated risk of ovarian cancer (OC). As only ~15% of OC individuals carry the pathogenic variants, the identification of other potential OC-susceptibility genes is of great clinical importance. Here, we established the prevalence and spectrum of the germline pathogenic variants in the and 23 other cancer-related genes in a large Polish population of 333 unselected OC cases. Approximately 21% of cases (71/333) carried the pathogenic or likely pathogenic variants, with c.5266dup (p.Gln1756Profs74) and c.3700_3704del (p.Val1234Glnfs8) being the most prevalent. Additionally, ~6% of women (20/333) were carriers of the pathogenic or likely pathogenic variants in other cancer-related genes, with and reported as the most frequently mutated, accounting for 1.8% (6/333) and 1.2% (4/333) of cases, respectively. We also found ten pathogenic or likely pathogenic variants in other genes: 1/333 in , 1/333 in , 2/333 in , 1/333 in , 1/333 in , 2/333 in , 1/333 in and 1/333 in , accounting for 50% of all detected variants in moderate- and low-penetrant genes. Our findings confirmed the presence of the additional OC-associated genes in the Polish population that may improve the personalized risk assessment of these individuals.

摘要

肿瘤抑制基因中的胚系功能丧失性致病变异与卵巢癌(OC)风险升高广泛相关。由于只有约15%的OC患者携带该致病变异,因此鉴定其他潜在的OC易感基因具有重要的临床意义。在此,我们在波兰一个由333例未经选择的OC病例组成的大群体中,确定了该基因以及其他与癌症相关的23个基因中胚系致病变异的流行情况和谱型。约21%的病例(71/333)携带该致病或可能致病的变异,其中c.5266dup(p.Gln1756Profs74)和c.3700_3704del(p.Val1234Glnfs8)最为常见。此外,约6%的女性(20/333)是其他癌症相关基因中致病或可能致病变异的携带者,其中报告的 和 是最常发生突变的,分别占病例的1.8%(6/333)和1.2%(4/333)。我们还在其他基因中发现了10个致病或可能致病的变异: 中1/333、 中1/333、 中2/333、 中1/333、 中1/333、 中2/333、 中1/333和 中1/333,占中低外显率基因中所有检测到变异的50%。我们的研究结果证实了波兰人群中存在其他与OC相关的基因,这可能会改善这些个体的个性化风险评估。

相似文献

1
Spectrum and Prevalence of Pathogenic Variants in Ovarian Cancer Susceptibility Genes in a Group of 333 Patients.333例患者卵巢癌易感基因致病变异的谱型及患病率
Cancers (Basel). 2018 Nov 14;10(11):442. doi: 10.3390/cancers10110442.
2
Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.1054 例乳腺癌阴性西班牙裔人群中 PALB2、CHEK2 和其他已知乳腺癌易感基因的致病性和可能致病性变异体。
Cancer. 2019 Aug 15;125(16):2829-2836. doi: 10.1002/cncr.32083. Epub 2019 Jun 17.
3
Pathogenic Variant Spectrum in Breast Cancer Risk Genes in Finnish Patients.芬兰患者乳腺癌风险基因中的致病变异谱
Cancers (Basel). 2022 Dec 14;14(24):6158. doi: 10.3390/cancers14246158.
4
Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients.通过下一代测序多基因panel 在 BRCAX 患者中鉴定 DNA 损伤修复基因的种系致病性变异。
Clin Biochem. 2020 Feb;76:17-23. doi: 10.1016/j.clinbiochem.2019.11.014. Epub 2019 Nov 28.
5
High frequency of pathogenic non-founder germline mutations in and in families with breast and ovarian cancer in a founder population.在一个奠基者群体中,乳腺癌和卵巢癌家族中BRCA1和BRCA2致病性非奠基者种系突变的高频率。
Hered Cancer Clin Pract. 2018 Jun 5;16:12. doi: 10.1186/s13053-018-0094-0. eCollection 2018.
6
Prevalence of pathogenic germline variants detected by multigene sequencing in unselected Japanese patients with ovarian cancer.在未经选择的日本卵巢癌患者中,通过多基因测序检测到的致病种系变异的患病率。
Oncotarget. 2017 Nov 28;8(68):112258-112267. doi: 10.18632/oncotarget.22733. eCollection 2017 Dec 22.
7
Recurrent Mutations in , , , and in Polish Patients with Ovarian Cancer.波兰卵巢癌患者中、、、及的复发性突变
Cancers (Basel). 2021 Feb 18;13(4):849. doi: 10.3390/cancers13040849.
8
Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer.针对因罕见基因导致乳腺癌和卵巢癌的女性的预防保健建议。
Klin Onkol. 2019 Summer;32(Supplementum2):6-13. doi: 10.14735/amko2019S6.
9
Genetic characterization of early onset ovarian carcinoma.早发性卵巢癌的基因特征分析
Gynecol Oncol. 2016 Feb;140(2):221-5. doi: 10.1016/j.ygyno.2015.12.017. Epub 2015 Dec 21.
10
Double heterozygous mutation in the BRCA1 and ATM genes involved in development of primary metachronous tumours: a case report.BRCA1 和 ATM 基因双重杂合突变与原发性异时性肿瘤的发生相关:病例报告。
Breast Cancer Res Treat. 2019 Oct;177(3):767-770. doi: 10.1007/s10549-019-05343-4. Epub 2019 Jul 10.

引用本文的文献

1
Assessment of candidate high-grade serous ovarian carcinoma predisposition genes through integrated germline and tumour sequencing.通过整合种系和肿瘤测序评估候选高级别浆液性卵巢癌易感基因
NPJ Genom Med. 2025 Jan 10;10(1):1. doi: 10.1038/s41525-024-00447-3.
2
A comprehensive analysis of germline predisposition to early-onset ovarian cancer.对早发性卵巢癌种系易感性的综合分析。
Sci Rep. 2024 Jul 13;14(1):16183. doi: 10.1038/s41598-024-66324-2.
3
Detection of Germline Mutations in a Cohort of 250 Relatives of Mutation Carriers in Multigene Panel: Impact of Pathogenic Variants in Other Genes beyond .

本文引用的文献

1
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.奥拉帕利维持治疗新诊断的晚期卵巢癌患者。
N Engl J Med. 2018 Dec 27;379(26):2495-2505. doi: 10.1056/NEJMoa1810858. Epub 2018 Oct 21.
2
Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing.大规模测序识别的乳腺癌和卵巢癌相关易感基因。
JAMA Oncol. 2019 Jan 1;5(1):51-57. doi: 10.1001/jamaoncol.2018.2956.
3
Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations.
在多基因检测板中对 250 名突变携带者亲属进行种系突变检测:除……之外其他基因中致病变异的影响
Cancers (Basel). 2023 Dec 6;15(24):5730. doi: 10.3390/cancers15245730.
4
Early-Onset Ovarian Cancer <30 Years: What Do We Know about Its Genetic Predisposition?早发性卵巢癌(<30 岁):其遗传易感性方面我们了解多少?
Int J Mol Sci. 2023 Nov 30;24(23):17020. doi: 10.3390/ijms242317020.
5
Targeted next-generation sequencing of 21 candidate genes in hereditary ovarian cancer patients from the Republic of Bashkortostan.巴什科尔托斯坦共和国遗传性卵巢癌患者 21 个候选基因的靶向二代测序。
J Ovarian Res. 2023 Apr 4;16(1):66. doi: 10.1186/s13048-023-01119-z.
6
DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities.卵巢癌中的DNA损伤反应改变:从分子机制到治疗机遇
Cancers (Basel). 2023 Jan 10;15(2):448. doi: 10.3390/cancers15020448.
7
DNA Repair Mechanisms, Protein Interactions and Therapeutic Targeting of the MRN Complex.MRN复合物的DNA修复机制、蛋白质相互作用及治疗靶点
Cancers (Basel). 2022 Oct 27;14(21):5278. doi: 10.3390/cancers14215278.
8
Genetic diversity in Kashubs: the regional increase in the frequency of several disease-causing variants.卡舒布人的遗传多样性:几种致病变体频率的区域性增加。
J Appl Genet. 2022 Dec;63(4):691-701. doi: 10.1007/s13353-022-00713-z. Epub 2022 Aug 15.
9
The prevalence of mismatch repair deficiency in ovarian cancer: A systematic review and meta-analysis.卵巢癌中错配修复缺陷的流行率:系统评价和荟萃分析。
Int J Cancer. 2022 Nov 1;151(9):1626-1639. doi: 10.1002/ijc.34165. Epub 2022 Jul 6.
10
Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors.卵巢癌、乳腺癌、结直肠癌、胰腺癌、非小细胞肺癌和前列腺癌中的同源重组缺陷以及对PARP抑制剂的耐药机制
Front Oncol. 2022 Jun 17;12:880643. doi: 10.3389/fonc.2022.880643. eCollection 2022.
BRCA1 或 BRCA2 突变 29700 个家系的世界性研究中的突变谱。
Hum Mutat. 2018 May;39(5):593-620. doi: 10.1002/humu.23406. Epub 2018 Mar 12.
4
Detection of Germline Mutations in Patients with Epithelial Ovarian Cancer Using Multi-gene Panels: Beyond BRCA1/2.使用多基因面板检测上皮性卵巢癌患者的种系突变:超越 BRCA1/2。
Cancer Res Treat. 2018 Jul;50(3):917-925. doi: 10.4143/crt.2017.220. Epub 2017 Sep 27.
5
Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer.鲁卡帕尼:一种新获批用于卵巢癌的聚(腺苷酸)核糖聚合酶(PARP)抑制剂的过去、现在与未来
Onco Targets Ther. 2017 Jun 19;10:3029-3037. doi: 10.2147/OTT.S114714. eCollection 2017.
6
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.BRCA1 和 BRCA2 基因突变携带者的乳腺癌、卵巢癌和对侧乳腺癌风险。
JAMA. 2017 Jun 20;317(23):2402-2416. doi: 10.1001/jama.2017.7112.
7
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017.NCCN 指南解读:遗传/家族性高风险评估:乳腺和卵巢,2017 年第 2 版。
J Natl Compr Canc Netw. 2017 Jan;15(1):9-20. doi: 10.6004/jnccn.2017.0003.
8
Antagonizing functions of BARD1 and its alternatively spliced variant BARD1δ in telomere stability.BRCA1相关蛋白1(BARD1)及其可变剪接变体BARD1δ在端粒稳定性中的拮抗功能
Oncotarget. 2017 Feb 7;8(6):9339-9353. doi: 10.18632/oncotarget.14068.
9
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.鲁卡帕利治疗复发铂类敏感型高级别卵巢癌(ARIEL2 研究第 1 部分):一项国际多中心、开放标签、2 期临床试验。
Lancet Oncol. 2017 Jan;18(1):75-87. doi: 10.1016/S1470-2045(16)30559-9. Epub 2016 Nov 29.
10
Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer.21401个乳腺癌和卵巢癌家族中BRCA1/2种系突变的患病率
J Med Genet. 2016 Jul;53(7):465-71. doi: 10.1136/jmedgenet-2015-103672. Epub 2016 Feb 29.